Hester Biosciences has received approval for the divestment of 43.81% equity shareholding out of total 54.81% in its subsidiary, Texas Lifesciences (TLPL), by way of transfer/sale of shares to the existing promoter shareholders of the TLPL. TLPL is not material subsidiary of the company. TLPL will ceased to be the subsidiary of the company upon completion share transfer transaction as above.
The consideration will receive from such sale/disposal is Rs 9.2 crore subject to terms and conditions of agreement. The transaction is expected to be completed within three months. The Board of Directors at the meeting held on March 11, 2026, and on the recommendations of the Audit Committee of the Board, considered and approved the same.
Hester Biosciences (Hester) is the largest poultry vaccine manufacturer and one of the leading animal healthcare companies in India.
